Antimicrobial resistance profiles of the imipenem-resistant Escherichia coli clinical isolates from 2011 to 2015
10.13699/j.cnki.1001-6821.2017.03.012
- VernacularTitle:2011年至2015年耐亚胺培南大肠埃希菌临床分离株的耐药性分析
- Author:
Han CHEN
1
;
Si-Si CHEN
;
Fang-You YU
Author Information
1. 温州医科大学附属第一医院检验科
- Keywords:
Escherichia coli;
imipenem;
resistance
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(3):232-234
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the distribution and antimicrobial resistance profiles of the imipenem-resistant Escherichia coli clinical isolates.Methods A total of 10428 Escherichia coli isolates were isolated from various specimens of patients at the first affiliated hospital of Wenzhou medical university from January 2011 to November 2015.The identification and antimicrobial susceptibility testing for Escherichia coli isolates were determined by VITEK Full Automated Microbiology Analyzer.Results Among 10428 Escherichia coli clinical isolates,including 62.69％ ESBLs-producing isolates,84(0.81％) were resistant to imipenem.The rates of imipenem resistance among Escherichia coli isolates from 2011 to 2015 were 0.14％ (2/1397 strains),0.47％ (9/1898strains),0.55％ (12/2170 strains),0.88％ (22/2489 strains) and 1.58％ (39/2474 strains).Among 84 imipenem-resistant isolates,50.00％ (42/84 strains) were ESBLs-producing isolates;the non-susceptibility rates of all imipenem-resistant isolates to cefazolin,ampicillin,ampicillin/sulbactam,ertapenem and ceftriaxone were more than 90.00％.However,the susceptibility rates of these isolates to nitrofurantion and amikacin were more than 50.00％ (50.00％ and 62.50％).The susceptibility rates of imipenem-resistant isolates to other types of antibiotics were less than 30.00％.Conclusion Imipenem has fine antimicrobial activity in vitro against Escherichia coli isolates.However,the prevalence of imipenem resistance among Escherichia coli clinical isolates is increasing year by year.
